177Lu and 227Th Labeled 3,4,3-(LI-1,2-HOPO): characterization, optimized synthesis, biological distribution and dosimetry
Objectives: Interest in targeted radionuclide therapy has greatly increased namely due to the FDA approval of radiotherapeutic drugs such as Lutathera The identification of chelators that can bind diag- nostic and therapeutic radionuclides would allow facile development of agents tailored for person...
Gespeichert in:
| Veröffentlicht in: | Nuclear medicine and biology 2022-12, Vol.114-115, p.S25-S26 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S26 |
|---|---|
| container_issue | |
| container_start_page | S25 |
| container_title | Nuclear medicine and biology |
| container_volume | 114-115 |
| creator | Sanders, Vanessa Phipps, Michael Demoin, Dustin Pratt, Edwin Bhupathiraju, N.V.S. Dinesh Ponnala, Shashikanth Ferdous, Jannatul Schlyer, David Carter, Lukas Lewis, Jason Deri, Melissa Cutler, Cathy Francesconi, Lynn |
| description | Objectives: Interest in targeted radionuclide therapy has greatly increased namely due to the FDA approval of radiotherapeutic drugs such as Lutathera The identification of chelators that can bind diag- nostic and therapeutic radionuclides would allow facile development of agents tailored for personalized medicine. Hydroxypyridinonate (HOPO) derivatives have been demonstrated as effective decorpo- ration agents for actinides owing to their hard oxygen donor atoms and strong complexation. Utilizing these molecules as chelators for potential nuclear medicine agents should allow for radiometals to be effectively sequestered by the ligand. The aim of this work was to evaluate the in vivo stability of 3-4-3-(LI-1,2-HOPO) (HOPO for short) with 177Lu and 227Th as potential beta- and alpha-emitting radiothera- peutic complexes, respectively. |
| doi_str_mv | 10.1016/S0969-8051(22)02144-8 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_1958592</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1016_S0969_8051_22_02144_8</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1208-dbbea5880b496541a91057df04cdc8c0d2f7a5f5e521a64c035c4d8d7828c0233</originalsourceid><addsrcrecordid>eNo9kEFLwzAYhoMoOKc_QQieNmg0SZM29SZD3aAwwXkOaZLaSNeOJDt0v95uE0_f4X3e94MHgHuCHwkm2dMnLrICCczJjNI5poQxJC7AhIicoiIj7BJM_pFrcBPCDx57jOAJGEiel3uoOgMpzTcNLFVlW2tgmrAkRbNyhUhC0XL9sZ4_Q90or3S03h1UdH2XwH4X3dYdxkIYutjY4EICK9e3_bfTqoXGhehdtT_Spy-mD25rox9uwVWt2mDv_u4UfL29bhZLVK7fV4uXEmlCsUCmqqziQuCKFRlnRBUE89zUmGmjhcaG1rniNbecEpUxjVOumREmF3RMaZpOwcN5tw_RyaBdtLrRfddZHSUpuOAFHSF-hrTvQ_C2ljvvtsoPkmB5lCxPkuXRoKRUniRLkf4Cawptdw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>177Lu and 227Th Labeled 3,4,3-(LI-1,2-HOPO): characterization, optimized synthesis, biological distribution and dosimetry</title><source>Access via ScienceDirect (Elsevier)</source><creator>Sanders, Vanessa ; Phipps, Michael ; Demoin, Dustin ; Pratt, Edwin ; Bhupathiraju, N.V.S. Dinesh ; Ponnala, Shashikanth ; Ferdous, Jannatul ; Schlyer, David ; Carter, Lukas ; Lewis, Jason ; Deri, Melissa ; Cutler, Cathy ; Francesconi, Lynn</creator><creatorcontrib>Sanders, Vanessa ; Phipps, Michael ; Demoin, Dustin ; Pratt, Edwin ; Bhupathiraju, N.V.S. Dinesh ; Ponnala, Shashikanth ; Ferdous, Jannatul ; Schlyer, David ; Carter, Lukas ; Lewis, Jason ; Deri, Melissa ; Cutler, Cathy ; Francesconi, Lynn ; Brookhaven National Laboratory (BNL), Upton, NY (United States)</creatorcontrib><description>Objectives: Interest in targeted radionuclide therapy has greatly increased namely due to the FDA approval of radiotherapeutic drugs such as Lutathera The identification of chelators that can bind diag- nostic and therapeutic radionuclides would allow facile development of agents tailored for personalized medicine. Hydroxypyridinonate (HOPO) derivatives have been demonstrated as effective decorpo- ration agents for actinides owing to their hard oxygen donor atoms and strong complexation. Utilizing these molecules as chelators for potential nuclear medicine agents should allow for radiometals to be effectively sequestered by the ligand. The aim of this work was to evaluate the in vivo stability of 3-4-3-(LI-1,2-HOPO) (HOPO for short) with 177Lu and 227Th as potential beta- and alpha-emitting radiothera- peutic complexes, respectively.</description><identifier>ISSN: 0969-8051</identifier><identifier>EISSN: 1872-9614</identifier><identifier>DOI: 10.1016/S0969-8051(22)02144-8</identifier><language>eng</language><publisher>United States: Elsevier</publisher><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><ispartof>Nuclear medicine and biology, 2022-12, Vol.114-115, p.S25-S26</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.osti.gov/servlets/purl/1958592$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanders, Vanessa</creatorcontrib><creatorcontrib>Phipps, Michael</creatorcontrib><creatorcontrib>Demoin, Dustin</creatorcontrib><creatorcontrib>Pratt, Edwin</creatorcontrib><creatorcontrib>Bhupathiraju, N.V.S. Dinesh</creatorcontrib><creatorcontrib>Ponnala, Shashikanth</creatorcontrib><creatorcontrib>Ferdous, Jannatul</creatorcontrib><creatorcontrib>Schlyer, David</creatorcontrib><creatorcontrib>Carter, Lukas</creatorcontrib><creatorcontrib>Lewis, Jason</creatorcontrib><creatorcontrib>Deri, Melissa</creatorcontrib><creatorcontrib>Cutler, Cathy</creatorcontrib><creatorcontrib>Francesconi, Lynn</creatorcontrib><creatorcontrib>Brookhaven National Laboratory (BNL), Upton, NY (United States)</creatorcontrib><title>177Lu and 227Th Labeled 3,4,3-(LI-1,2-HOPO): characterization, optimized synthesis, biological distribution and dosimetry</title><title>Nuclear medicine and biology</title><description>Objectives: Interest in targeted radionuclide therapy has greatly increased namely due to the FDA approval of radiotherapeutic drugs such as Lutathera The identification of chelators that can bind diag- nostic and therapeutic radionuclides would allow facile development of agents tailored for personalized medicine. Hydroxypyridinonate (HOPO) derivatives have been demonstrated as effective decorpo- ration agents for actinides owing to their hard oxygen donor atoms and strong complexation. Utilizing these molecules as chelators for potential nuclear medicine agents should allow for radiometals to be effectively sequestered by the ligand. The aim of this work was to evaluate the in vivo stability of 3-4-3-(LI-1,2-HOPO) (HOPO for short) with 177Lu and 227Th as potential beta- and alpha-emitting radiothera- peutic complexes, respectively.</description><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><issn>0969-8051</issn><issn>1872-9614</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNo9kEFLwzAYhoMoOKc_QQieNmg0SZM29SZD3aAwwXkOaZLaSNeOJDt0v95uE0_f4X3e94MHgHuCHwkm2dMnLrICCczJjNI5poQxJC7AhIicoiIj7BJM_pFrcBPCDx57jOAJGEiel3uoOgMpzTcNLFVlW2tgmrAkRbNyhUhC0XL9sZ4_Q90or3S03h1UdH2XwH4X3dYdxkIYutjY4EICK9e3_bfTqoXGhehdtT_Spy-mD25rox9uwVWt2mDv_u4UfL29bhZLVK7fV4uXEmlCsUCmqqziQuCKFRlnRBUE89zUmGmjhcaG1rniNbecEpUxjVOumREmF3RMaZpOwcN5tw_RyaBdtLrRfddZHSUpuOAFHSF-hrTvQ_C2ljvvtsoPkmB5lCxPkuXRoKRUniRLkf4Cawptdw</recordid><startdate>20221208</startdate><enddate>20221208</enddate><creator>Sanders, Vanessa</creator><creator>Phipps, Michael</creator><creator>Demoin, Dustin</creator><creator>Pratt, Edwin</creator><creator>Bhupathiraju, N.V.S. Dinesh</creator><creator>Ponnala, Shashikanth</creator><creator>Ferdous, Jannatul</creator><creator>Schlyer, David</creator><creator>Carter, Lukas</creator><creator>Lewis, Jason</creator><creator>Deri, Melissa</creator><creator>Cutler, Cathy</creator><creator>Francesconi, Lynn</creator><general>Elsevier</general><scope>AAYXX</scope><scope>CITATION</scope><scope>OIOZB</scope><scope>OTOTI</scope></search><sort><creationdate>20221208</creationdate><title>177Lu and 227Th Labeled 3,4,3-(LI-1,2-HOPO): characterization, optimized synthesis, biological distribution and dosimetry</title><author>Sanders, Vanessa ; Phipps, Michael ; Demoin, Dustin ; Pratt, Edwin ; Bhupathiraju, N.V.S. Dinesh ; Ponnala, Shashikanth ; Ferdous, Jannatul ; Schlyer, David ; Carter, Lukas ; Lewis, Jason ; Deri, Melissa ; Cutler, Cathy ; Francesconi, Lynn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1208-dbbea5880b496541a91057df04cdc8c0d2f7a5f5e521a64c035c4d8d7828c0233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanders, Vanessa</creatorcontrib><creatorcontrib>Phipps, Michael</creatorcontrib><creatorcontrib>Demoin, Dustin</creatorcontrib><creatorcontrib>Pratt, Edwin</creatorcontrib><creatorcontrib>Bhupathiraju, N.V.S. Dinesh</creatorcontrib><creatorcontrib>Ponnala, Shashikanth</creatorcontrib><creatorcontrib>Ferdous, Jannatul</creatorcontrib><creatorcontrib>Schlyer, David</creatorcontrib><creatorcontrib>Carter, Lukas</creatorcontrib><creatorcontrib>Lewis, Jason</creatorcontrib><creatorcontrib>Deri, Melissa</creatorcontrib><creatorcontrib>Cutler, Cathy</creatorcontrib><creatorcontrib>Francesconi, Lynn</creatorcontrib><creatorcontrib>Brookhaven National Laboratory (BNL), Upton, NY (United States)</creatorcontrib><collection>CrossRef</collection><collection>OSTI.GOV - Hybrid</collection><collection>OSTI.GOV</collection><jtitle>Nuclear medicine and biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanders, Vanessa</au><au>Phipps, Michael</au><au>Demoin, Dustin</au><au>Pratt, Edwin</au><au>Bhupathiraju, N.V.S. Dinesh</au><au>Ponnala, Shashikanth</au><au>Ferdous, Jannatul</au><au>Schlyer, David</au><au>Carter, Lukas</au><au>Lewis, Jason</au><au>Deri, Melissa</au><au>Cutler, Cathy</au><au>Francesconi, Lynn</au><aucorp>Brookhaven National Laboratory (BNL), Upton, NY (United States)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>177Lu and 227Th Labeled 3,4,3-(LI-1,2-HOPO): characterization, optimized synthesis, biological distribution and dosimetry</atitle><jtitle>Nuclear medicine and biology</jtitle><date>2022-12-08</date><risdate>2022</risdate><volume>114-115</volume><spage>S25</spage><epage>S26</epage><pages>S25-S26</pages><issn>0969-8051</issn><eissn>1872-9614</eissn><abstract>Objectives: Interest in targeted radionuclide therapy has greatly increased namely due to the FDA approval of radiotherapeutic drugs such as Lutathera The identification of chelators that can bind diag- nostic and therapeutic radionuclides would allow facile development of agents tailored for personalized medicine. Hydroxypyridinonate (HOPO) derivatives have been demonstrated as effective decorpo- ration agents for actinides owing to their hard oxygen donor atoms and strong complexation. Utilizing these molecules as chelators for potential nuclear medicine agents should allow for radiometals to be effectively sequestered by the ligand. The aim of this work was to evaluate the in vivo stability of 3-4-3-(LI-1,2-HOPO) (HOPO for short) with 177Lu and 227Th as potential beta- and alpha-emitting radiothera- peutic complexes, respectively.</abstract><cop>United States</cop><pub>Elsevier</pub><doi>10.1016/S0969-8051(22)02144-8</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0969-8051 |
| ispartof | Nuclear medicine and biology, 2022-12, Vol.114-115, p.S25-S26 |
| issn | 0969-8051 1872-9614 |
| language | eng |
| recordid | cdi_osti_scitechconnect_1958592 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | RADIOLOGY AND NUCLEAR MEDICINE |
| title | 177Lu and 227Th Labeled 3,4,3-(LI-1,2-HOPO): characterization, optimized synthesis, biological distribution and dosimetry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T19%3A09%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=177Lu%20and%20227Th%20Labeled%203,4,3-(LI-1,2-HOPO):%20characterization,%20optimized%20synthesis,%20biological%20distribution%20and%20dosimetry&rft.jtitle=Nuclear%20medicine%20and%20biology&rft.au=Sanders,%20Vanessa&rft.aucorp=Brookhaven%20National%20Laboratory%20(BNL),%20Upton,%20NY%20(United%20States)&rft.date=2022-12-08&rft.volume=114-115&rft.spage=S25&rft.epage=S26&rft.pages=S25-S26&rft.issn=0969-8051&rft.eissn=1872-9614&rft_id=info:doi/10.1016/S0969-8051(22)02144-8&rft_dat=%3Ccrossref_osti_%3E10_1016_S0969_8051_22_02144_8%3C/crossref_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |